Key Points
- Life Sciences Xi L.P. Frazier purchased 588,235 Attovia Therapeutics shares at $17 each, investing approximately $10 million and increasing its position by 10.57% to 6,154,213 shares.
- The transaction was disclosed in a filing with the Securities and Exchange Commission, as required for shareholders owning more than 10% of a company.
- Attovia shares were trading down 6.9%, opening at $20.38, while the clinical-stage biotechnology company continues developing antibody-based treatments for inflammatory and immune-mediated diseases.
Attovia Therapeutics, Inc. (NASDAQ:ATTO - Get Free Report) major shareholder Life Sciences Xi L.P. Frazier purchased 588,235 shares of the business's stock in a transaction dated Thursday, August 6th. The shares were purchased at an average price of $17.00 per share, with a total value of $9,999,995.00. Following the purchase, the insider directly owned 6,154,213 shares in the company, valued at $104,621,621. This trade represents a 10.57% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Attovia Therapeutics Trading Down 6.9%
Shares of NASDAQ ATTO opened at $20.38 on Friday. Attovia Therapeutics, Inc. has a fifty-two week low of $19.63 and a fifty-two week high of $22.79.
About Attovia Therapeutics
(
Get Free Report)
Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company's research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.
Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
